Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GPhA Enters 2011 Bigger And Stronger, But With A Broader Fight On Its Hands

Executive Summary

The Generic Pharmaceutical Association is pretty fond of Florida. The group has held its annual meeting in the state almost every year since the association was formed. But regardless of the weather or the hotel amenities, when GPhA convenes in Orlando next month, its members will be slightly disappointed in the venue: Florida is below the national average in the generic utilization rate for its Medicaid program.

You may also be interested in...

GPhA And Actavis Divorcing: Biosimilars Behind The Rift

Actavis, the hybridizing generics giant that once helped keep GPhA together, now appears to be splitting off in a dispute over state substitution strategy.

GPhA’s Goals For 2013: Smooth GDUFA Implementation, Workable Biosimilar Pathway

The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.

GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience

When Ralph Neas joins the Generic Pharmaceutical Association as CEO on Sept. 12 he will face many of the same challenges he’s had as CEO of the National Coalition on Health Care: energizing reform-minded partners to advocate for legislative and policy changes.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts